NCT03545815Unknown1 期
Phase I Study to Evaluate Treatment of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Chimeric Antigen Receptor (CAR) T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
Chinese PLA General Hospital2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年3月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- study of related adverse events
研究概览
简要总结
Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric antigen receptor (CAR) T cells to effect the immuno-microenvironment around tumors.
详细描述
- To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out chimeric antigen receptor (CAR) T cells in patients with mesothelin positive multiple solid tumors.
- To evaluate the duration of in vivo persistence of transferred CAR-T cells.
- To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed with mesothelin positive multiple solid tumors.
- •Failure of at least one prior standard of care chemotherapy for advanced stage disease.
- •Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria.
- •Patients > 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Life expectancy > 12 weeks.
- •Satisfactory organ and bone marrow function as defined by the following (of note, the minimal blood counts should be in the absence of transfusion or cytokine support):
- •i. Absolute neutrophil count > 1,000/μl ii. Platelets >75,000/μl iii. Hemoglobin > 9 g/dL iv. Bilirubin < 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine < 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5x the institutional normal upper limit viii. Cardiac ejection fraction of >55% as measured by resting echocardiogram, with no significant pericardial effusion.
- •Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT < 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.
- •Ability to understand and the willingness to provide written informed consent.
- •Male and Female subjects of reproductive potential agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) and abstain from other methods of conception during the study and for 6 months following the study cell infusion or proof of sterility.
排除标准
- •Sarcomatoid MPM histology which is known in the literature to not express mesothelin; biphasic MPM is also excluded.
- •This refers to non-commercially approved investigational drugs different than those used in this protocol.Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to enrollment and anticipated treatment with another investigational product while on study.
- •Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion of CART-meso cells.
- •Active invasive cancer other than the one of the three cancers in this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded.CART-meso in mesothelin expressing cancers
- •HIV, HCV, or HBV infections
- •Active autoimmune disease (including but not limited to: systemic lupus erythromatosis, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks, with exception of thyroid replacement.
- •Patients with ongoing or active infection.
- •Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10mg equivalent of prednisone) for chronic respiratory conditions.
- •Patients requiring supplemental oxygen therapy.
- •Prior therapy with gene modified cells.
- •Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human and humanized antibodies are allowed).
- •History of allergy to murine proteins
- •History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
- •Any clinically significant pericardial effusion; CHF (NY Heart Association Grade II-IV) or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist.
- •Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to enrollment is acceptable.
- •Pregnant or breastfeeding women. Female study participants of reproductive potential must have a negative urine pregnancy test of enrollment. A serum pregnancy test will be performed within 2 weeks before infusion.
结局指标
主要结局
study of related adverse events
时间窗: 24 weeks
Grade 3 signs/symptoms, toxicities and clinical
次要结局
- clinical responses to anti-mesothelin cell infusions(24 weeks)
研究者
Han weidong
Director
Chinese PLA General Hospital
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid TumorsSolid Tumor, AdultNCT03747965Chinese PLA General Hospital10
已完成
不适用
Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerOvarian CancerNCT05372692Weijia Fang, MD3
已完成
1 期
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsNeoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, ExtrahepaticAdenocarcinoma, PancreaticNCT04034238National Cancer Institute (NCI)19
终止
1 期
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaMesotheliomaNCT03436732National Cancer Institute (NCI)5
已完成
1 期
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express MesothelinAdvanced Recurrent Malignant Pleural Epithelioid MesotheliomaAdvanced Recurrent Malignant Peritoneal Epithelioid MesotheliomaAdvanced Recurrent Serous Ovarian CancerAdvanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)NCT03507452Bayer36